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Abstract
Immunotherapy is now widely established as a potent and effective treatment option across several types of
cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention
on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and
mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in
combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of
particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head
and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28–29 November, 2018,
Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key
presentations from this meeting are summarised in this report.
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Introduction
Immunotherapy is now established as a potent and ef-
fective treatment option across several cancer types.
However, there is an increased recognition that not all
patients respond to immunotherapy, highlighting the im-
portance of the immune contexture of the tumor micro-
environment (TME) as a driver of the immune response
and tumor resistance to immunity and stressing the
need for the development of novel immunotherapeutics
and for their use in combination with checkpoint inhibi-
tors and other standard of care and novel treatment mo-
dalities. The 4th Immunotherapy Bridge meeting (28–29
November, 2018, Naples, Italy) was focused on evolving
topics and trends in cancer immunotherapy and is sum-
marised in this report.
Evolving topics in cancer immunotherapy: tumor
microenvironment
Reprogramming the tumor microenvironment and T-cells
for immunotherapy of ovarian cancer
Immune checkpoint inhibitors demonstrate promising
but modest results in ovarian cancer (Table 1).
In the KEYNOTE-100 trial, an overall response rate
(ORR) of 8% was reported in patients with advanced re-
current ovarian cancer treated with pembrolizumab, with
29% of patients having stable disease [1]. PD-1 pathway
blockade is only of limited benefit in ovarian cancer be-
cause of multiple immune suppressive networks in the
TME. The challenge is how to increase antitumor T cell
frequency and function through reprogramming the TME
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and promoting the persistence of anti-tumor T cells. One
strategy is to utilize the cell destructive properties of onco-
lytic viruses. For instance, intratumoral administration of
talimogene laherparepvec (T-VEC) plus pembrolizumab
has been shown to increase CD8 infiltration and resulted
in a 62% ORR in melanoma [2]. Different classes of onco-
lytic virus are currently being examined in ovarian cancer,
including antigen-armed approaches. One of these is Pox-
viridae armed with a CXCR4 inhibitor. The CXCR4 re-
ceptor is one of the key stimuli involved in signaling
interactions between tumor cells and their stromal micro-
environment and is pivotal for metastasis and immune
suppression within the ovarian TME. CXCR4 overexpres-
sion is related to an aggressive phenotype and poor progno-
sis in ovarian cancer and is essential for cancer-initiating cell
maintenance, dissemination and metastatic spread to organs
where CXCL12 is expressed. In an orthotopic ID8-T tumor
model, a CXCR4 antagonist-expressing oncolytic vaccinia
virus (OVV-CXCR4-Fc) led to reduced metastatic spread of
tumors and improved overall survival (OS) compared with
oncolysis alone. Inhibition of tumor growth was associated
with reduced recruitment of T regulatory cells (Tregs), and
higher ratios of interferon (IFN)-γ/interleukin (IL)-10+
tumor-infiltrating lymphocytes (TILs), as well as induction
of spontaneous humoral and cellular antitumor responses
[3]. Another strategy may be to use adoptive cell transfer
(ACT) to render T cells resistant to immunosuppression by
transforming growth factor (TGF)-β in order to promote
persistence. The safety and feasibility of ACT has been
established and a trial of NY-ESO-1T-cell receptor (TCR)
in ovarian cancer patients which offered evidence of adap-
tive immune resistance [4]. However, poor persistence may
limit its use. Intrinsic TGFβ signaling blockade enhances
in vivo persistence and a phase I/IIa study of TGFß blockade
in TCR-engineered T cell cancer immunotherapy is now be-
ing assessed in patients with advanced malignancies.
Key points
 PD-1 pathway blockade is only of limited benefit in
ovarian cancer because of multiple immune
suppressive networks in the TME.
 Different classes of oncolytic virus are currently
being evaluated in ovarian cancer, including
Poxviridae armed with a CXCR4 inhibitor and a
CXCR4 antagonist-expressing oncolytic vaccinia
virus (OVV-CXCR4-Fc).
 Another strategy may be to use ACT to render T
cells resistant to immunosuppression by TGF-β in
order to promote persistence.
 A phase I/IIa study of TGFß blockade in TCR-
engineered T cell cancer immunotherapy is being
conducted in patients with advanced malignancies.
The contribution of tumor-residing dendritic cells to an
anti-tumor immune response
CD8+ T cell inflammation is associated with an increased
response to checkpoint blockade therapy. Tumor cell-
Table 1. Reported results of checkpoint blockade in ovarian cancer.
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intrinsic signaling pathways directly impact T cell infiltra-
tion into the TME. Molecular analysis of human meta-
static melanoma samples revealed a correlation between
activation of the WNT/β-catenin signalling pathway and
absence of a T-cell gene expression signature [5]. Using a
mouse melanoma model, a mechanism by which tumor-
intrinsic active β-catenin signalling resulted in T-cell
exclusion and resistance to anti-PD-L1/anti-cytotoxic T-
lymphocyte-associated antigen (CTLA)-4 therapy was
identified. Lack of CD103+ dendritic cells (DCs) was asso-
ciated with reduced priming of tumor-specific T cells.
Adoptive transfer of effector 2C T cells fails to control β-
catenin-expressing tumors. T cells remain motile and mi-
grate in a directional fashion after tumor eradication.
However, β-catenin-expressing tumors show reduced
tumor-reactive 2C T cell numbers with reduced motility.
CD103+ dendritic cells are the predominant source of
CXCR3 chemokine ligands and tumor-residing Batf3-
driven CD103+ DCs are required for the recruitment of
effector T cells into the TME as well as T cell priming in
the tumor-draining lymph nodes [6]. Understanding the
role of tumor-resident DCs may be important in improv-
ing response to immunotherapy. Regressing and progres-
sing tumors exhibit differences in DC composition, with
regressing tumors having higher numbers of cross-
presenting DCs and CD8+ T cells. Regressing tumors
mount T cell responses independent of CD103+ DC and
conventional cross-presentation. Single cell RNA-
sequencing has revealed new subsets of DCs associated
with regressing tumors and thus associated with a highly
productive anti-tumor immune response. A working hy-
pothesis is that productive anti-tumor immunity depends
on multiple tumor-resident DC subsets with cross-
presenting capabilities.
Key points
 Anti-tumor immune responses depend on priming
and recruitment of CD8+ T cells.
 CD103+ cross-presenting DCs mediate priming and
recruitment of CD8+ T cells into the TME.
 Tumor clearance is associated with prolonged
functionality of cytotoxic T cells.
 New tumor-resident DC subsets have been identified
associated with highly potent anti-tumor immunity.
Understanding the immune composition and therapeutic
implications of human lung cancer
The identification of predictive biomarkers is one of the
major challenges in the field of immuno-oncology. Di-
verse biomarkers, including both phenotypic and gen-
omic metrics, have shown association with benefit from
PD-1/PD-L1 agents (Fig. 1).
However, the clinical use of these tests is limited by their
suboptimal performance and limited understanding of their
biological significance. To date, only elevated baseline PD-
L1 and high microsatellite instability (MSI-H) have been
approved for clinical use in multiple tumor types.
Emerging biomarkers such as tumor T-cell infiltration
(or associated mRNA signatures) and increased tumor
mutational burden may provide additional clinical value.
In previous studies using multiplexed and quantitative
immunofluorescence analysis of major tumor-infiltrating
lymphocyte (TIL) subpopulations, we have shown that
increased levels of CD3 and CD8+ TILs are associated
with better outcome in NSCLC, but only CD8 is inde-
pendent from other prognostic variables [7].
Paired whole exome DNA sequencing and multiplexed
quantitative immunofluorescence in pre-treatment sam-
ples from patients with NSCLC treated with PD-1 axis
blockers revealed that elevated mutational load, candi-
date class-I neoantigens and intratumoral CD3 signal are
significantly associated with favourable response to ther-
apy [8]. Moreover, a ‘dormant’ TIL signature character-
ized by elevated TILs with low or moderate activation
and proliferation was associated with a survival benefit
in patients treated with immune checkpoint blockers.
Dormant TILs were reinvigorated by PD-1 blockade in a
patient-derived xenograft model. NSCLC can be strati-
fied using T-cell markers into non-inflamed/poorly
inflamed tumors (with low or virtual absence of CD3+
cells) and inflamed tumors with either low or moderate
activation/proliferation (high CD3/low/modGZB and Ki-
67) or high activation/proliferation (high CD3/high GZB
or Ki-67). The presence of increased survival benefit in
tumors with a “dormant” TIL phenotype than in “cold
tumors” lacking TILs or in inflamed tumors with
marked T-cell activation and proliferation indicate that
effective immune stimulation using PD-1 axis blockers
requires T-cells with specific functional profiles. Highly
active/proliferating TILs may not be most sensitive to
single-agent PD-1 blockade and this could be due, at
least in part, to the common upregulation of multiple
co-inhibitory signals in these cells.
PD-1, T cell immunoglobulin, mucin-3 (TIM-3) and
lymphocyte activation gene 3 (LAG-3) are expressed in a
proportion of NSCLCs with signals predominantly lo-
cated in CD3+ T-cells [9].
These markers are positively associated with TILs and
with each other; and negatively associated with KRAS
and EGFR mutations in lung adenocarcinomas. In
NSCLC patients with acquired resistance to PD-1 block-
ing agents, higher levels of TIL activation (granzyme B),
proliferation (Ki-67), PD-1, TIM-3 and LAG-3 were as-
sociated with progression on-treatment [10]. Although
multiple mechanisms may exist, up-regulation of im-
mune inhibitory receptors such as TIM-3 and LAG-3
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could mediate resistance to PD-1 axis blockers in a pro-
portion of NSCLCs. Advanced analysis of the tumor im-
mune contexture using a 29-marker imaging mass
cytometry (IMC) panel showed increased CD4+/CD8+/
CD20+ TILs with higher expression of functional
markers in NSCLCs than case-matched non-tumor lung
tissue [11]. Prominent differences in the T-cell profile
were observed between patients with durable clinical
benefit from immune checkpoint blockade compared
with those without benefit, characterized by higher levels
of effector memory CD8+/CD45RO+ TILs and lower
levels of T-cell immune inhibitory receptors. Primary re-
sistance to treatment was associated with CD4+ or
CD8+ TILs containing increased levels of both activation
(CD25/TBET/GZB/Ki-67) and immune suppression/dys-
function markers (PD-1/LAG-3/TIM-3/FOXP3). Taken
together, these results suggest that prominent sensitivity
to PD-1 axis blockers in NSCLC requires a defined tumor
microenvironment characterized by the presence of TILs
with a balanced activation/regulation profile. Expansion of
these studies in larger cohorts and using computational
multiparametric analysis is ongoing. Deep analysis of in-
tact tumor specimens, circulating biomarkers and imaging
and integration of data and computational analysis will be
critical in identifying biomarkers that can be used to guide
optimal immunotherapy.
Key points
 Emerging biomarkers such as tumor T-cell infiltra-
tion (or associated mRNA signatures) and increased
tumor mutational burden may be of clinical value.
 Sensitivity to PD-1 axis blockers in NSCLC requires
a defined tumor microenvironment characterized by
the presence of TILs with a balanced activation/
regulation profile.
 Deep analysis of intact tumor specimens, circulating
biomarkers and imaging and integration of data and
computational analysis will be critical in identifying
biomarkers that can be used to guide optimal
immunotherapy.
Fine-tuning T cell signal strength for optimal cancer
immunotherapy
Although ACT is promising, how to improve the potency
of TILs and chimeric antigen receptor (CAR) T cells for
ACT is a critical issue. One solution may be to decrease the
number of beads used in the TIL or CAR culture. Magnetic
beads with CD3 and CD28 profoundly expand T cells, with
three beads for one T cell the standard formula for CAR
protocols. CD3/CD28 beads result in sustained logarithmic
T cell growth, with T cells progressively differentiating into
different effector T cells.
The use of 30-fold fewer Th17/CD3 ICOS beads per T
cells still results in T cell growth and expansion. More-
over, T cell function is dramatically changed by using
fewer beads, with T cells produced having greater func-
tionality. A low signal strength induced polyfunctional
cells, with a profound increase in cytokine production,
including IL-17, IFN-γ, IL-22 and IL-2. T cells produced
with fewer beads also had a less differentiated (‘younger’)
phenotype. In a murine model, T cells produced with
fewer beads resulted in a more effective antigen re-
sponse. Low signal strength T cells also have a distinct
metabolic profile characterized by reduced glycolytic ac-
tivity and a higher spare respiratory capacity and oxida-
tive phosphorylation.
Overexpression of phosphoenolpyruvate carboxy kin-
ase 1 (PCK1) boosts the activity of murine CD4+ T cells,
Fig. 1 Phenotypic and genomic biomarkers associated with clinical benefit from anti-PD-1/PD-L1 therapy
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due to upregulation of phosphoenolpyruvate (PEP).
Medium signal strength T cells express more PEP than
high signal strength T cells. However, overexpressing
PCK1 in high-stimulated CAR human Th17 cells can
augments antitumor immunity. Thus, it may also be
possible to engineer T cells with a modified metabolic
profile leading to increased antitumor efficacy.
Key points
 Improving the potency of TILs and CAR T cells for
ACT is a critical issue.
 One option may be to decrease the number of beads
used in the TIL or CAR culture, with T cells using
fewer beads associated with greater functionality and
a profound increase in cytokine production.
 It may be possible to engineer T cells with a
modified metabolic profile leading to increased
antitumor efficacy, such as through overexpression
of PCK1 in high-stimulated CAR human Th17 cells.
Overcoming metabolic barriers to effective antitumor
immunity
The TME has an immunosuppressive landscape and en-
gages in some very immunosuppressive functions. These
include altering stromal cell function to support tumor
growth, changing angiogenesis patterns, existing in mul-
tiple differentiation states, providing chronic antigen
stimulation and recruitment of immunosuppressive cell
types. However, a common phenotype of cancer is that it
is hungry. Thus, the TME, driven by the metabolic de-
rangement of tumor cells, generates a distinct metabolic
landscape, involving hypoxia, lactic acidosis, hypoglycemia
and essential amino acid depletion. An important question
is whether the TMEs metabolic landscape presents a bar-
rier to antitumor immunity and immunotherapy response.
TIL are rendered metabolically insufficient and intratu-
moral T cells, especially CD8s, have striking metabolic de-
fects. T cells infiltrating murine and human tumors
demonstrate persistent loss of mitochondrial function and
mass with repressed mitochondrial biogenesis causing T
cell metabolic insufficiency [12]. However, enforcing mito-
chondrial biogenesis in tumor-specific T cells renders T
cells resistant to metabolic insufficiency, which raises the
question of whether metabolic support can be provided to
T cells already in the TME.
Metabolic modulatory strategies to improve immuno-
therapies include genetic engineering approaches, the
stimulation of programs that promote mitochondrial
health, and pharmacological strategies to metabolically
reprogram T cells (Table 2).
However, the TME still presents metabolic barriers.
Even if T cells are metabolically more competitive, they
must still deal with the harsh conditions of the tumor.
In addition, it is thought that there is vast metabolic het-
erogeneity in tumors, from tissue type, interpatient, and
even between metastases of the same patient. Melanoma
cell lines display considerable metabolic heterogeneity
which can affect response to anti-PD-1 therapy. Oxida-
tive, but not glycolytic, tumor cell metabolism prior to ini-
tiation of anti-PD-1 therapy was associated with a poor
clinical outcome and, even in responding patients, low
tumor oxygen consumption rates were associated with in-
creased duration of response. Thus, tumor hypoxia is as-
sociated with resistance to PD-1 blockade. Therapeutic
targeting of oxidative metabolism may be potentially
beneficial. Metformin, a widely prescribed type 2 diabetes
treatment, inhibited oxygen consumption in tumor cells
in murine tumor lines resulting in reduced intratumoral
hypoxia [13]. Combination of metformin with PD-1 block-
ade resulted in improved intratumoral T-cell function and
tumor clearance. Metformin is now being assessed in
combination with anti-PD-1 inhibitors in clinical trials in
melanoma, squamous cell carcinoma of the head and neck
(SCCHN) and colorectal cancer.
Key points
 The TME generates a distinct metabolic landscape,
which may present a barrier to antitumor immunity
and immunotherapy response.
 Tumor hypoxia is associated with resistance to PD-1
blockade and targeting of oxidative metabolism may
be potentially beneficial.
 Metformin, a widely prescribed type 2 diabetes
treatment, inhibited oxygen consumption in tumor
cells in murine tumor lines resulting in reduced
intratumoral hypoxia and is now being assessed in
combination with anti-PD-1 inhibitors in clinical
trials.
Immunotherapy in the neck: what’s new?
The treatment of patients with recurrent or metastatic
locally advanced HNSCC is rapidly evolving. Cetuximab
in combination with platinum and 5-fluorouracil still re-
mains the standard of care as the first-line treatment.
However, results of the CheckMate 141 trial appear to
offer the first effective “second line” treatment after sev-
eral years of failures. In this randomized phase III trial,
patients with recurrent HNSCC whose disease had pro-
gressed within 6 months after platinum-based chemo-
therapy, nivolumab resulted in significantly longer OS
compared with standard therapy (methotrexate, doce-
taxel, or cetuximab) [14]. However, only a small propor-
tion of patients were responsive to nivolumab (13.3%
versus 5.8% with standard therapy) and no predictive
markers of response were identified. Similarly, first line
treatment with pembrolizumab significantly improved
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OS compared with cetuximab plus carboplatin or cis-
platin (EXTREME) in patients with increased PD-L1
expression and was non-inferior in the total population
in the KEYNOTE-048 trial [15]. Pembrolizumab plus
cisplatin or carboplatin significantly improved OS versus
EXTREME in the total population. Pembrolizumab also
had a favorable safety profile versus EXTREME and
these data support pembrolizumab monotherapy as a
new first-line standard of care for PD-L1+ recurrent
HNSCC.
Several promising immunotherapy agents are also
under development in head and neck cancer, including
toll-like receptor (TLR)-agonists, αSTAT-3, αNKG2A,
and αTGF-β. SD-101 is an agonist of TLR9 that stimu-
lates DCs to release IFN-α and mature into antigen-
presenting cells to activate T cell anti-tumor responses.
In anti-PD-1 treatment-naïve recurrent and/or meta-
static HNSCC patients, SD-101 in combination with
pembrolizumab showed a promising response rate,
appearing to enhance the systemic effect of anti-PD-1
blockade, and was well tolerated [16]. The TGF-β path-
way promotes tumor immunosuppression and its inhib-
ition may enhance the antitumor activity of PD-1/PD-L1
inhibitors. M7824 is a bifunctional fusion protein com-
posed of an anti-PD-L1 fused with the extracellular
domain of TGF-βRII. In a phase I trial, M7824 showed
promising clinical activity (ORR of 22%) and a manage-
able safety profile in patients with refractory/metastatic
HNSCC [17].
There was a possible trend toward higher activity in
HPV+ patients (ORR 50%) and evidence of clinical activity
irrespective of PD-L1 status. In another study, danvatirsen,
an antisense oligonucleotide STAT3 inhibitor, resulted in a
higher response rate in combination with durvalumab ver-
sus durvalumab monotherapy in PD-L1 treatment-naïve
patients with recurrent/metastatic-HNSCC [18].
Targeting new inhibitory receptors other than PD-(L)1
may also have a potential role. Monalizumab targets
NKG2A receptors expressed on tumor-infiltrating cyto-
toxic NK and CD8 T lymphocytes. Preliminary data sug-
gest promising antitumor activity of monalizumab in
combination with cetuximab in patients with HNSCC
progressing after platinum-based therapy with accept-
able safety [19].
Key points
 PD-1 inhibitors have shown promising results in
patients with recurrent or metastatic locally
advanced SCCHN and data support pembrolizumab
monotherapy as a new first-line standard of care for
PD-L1+ recurrent SCCHN.
 Several promising immunotherapy agents are under
development in head and neck cancer, including
TLR-agonists, αSTAT-3, αNKG2A, and αTGF-β.
 Targeting inhibitory receptors other than PD-(L)1
may also have a potential role; monalizumab targets
NKG2A receptors expressed on tumor-infiltrating
Table 2. Metabolic modulatory strategies to improve various cancer immunotherapies.
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cytotoxic NK and CD8 T lymphocytes and prelimin-
ary data suggest promising antitumor activity in
combination with cetuximab.
Immunotherapy in GU: what’s new?
In the phase III CheckMate-214 trial, OS and ORR were sig-
nificantly higher with nivolumab plus ipilimumab than with
sunitinib among intermediate-risk and poor-risk patients
with previously untreated advanced renal-cell carcinoma
(RCC) [20]. 18-month OS rate was 75% with nivolumab plus
ipilimumab and 60% with sunitinib. Treatment-related ad-
verse events leading to discontinuation occurred in 22% of
patients in the nivolumab plus ipilimumab group and 12%
of patients in the sunitinib group. Nivolumab plus ipilimu-
mab represents a new standard of care for intermediate- or
poor-risk advanced RCC. In the IMmotion151 trial, atezoli-
zumab was combined with bevacizumab and compared with
sunitinib as first-line treatment in metastatic RCC. Median
progression-free survival (PFS) was significantly longer with
atezolizumab plus bevacizumab in patients with PD-L1 ex-
pression (≥1%) (11.2 versus 7.7months with sunitinib) and
tolerability was consistent with monotherapies [21]. Tumor
molecular analyses showed that high T effector/IFN-γ (Teff)
gene expression signature was associated with PD-L1 ex-
pression and longer PFS for atezolizumab plus bevacizumab
compared to sunitinib [22]. Angiogenesis gene expression
was higher in the favorable Memorial Sloan Kettering Can-
cer Center (MSKCC) risk group but lower in sarcomatoid
tumors, in which PD-L1 expression was higher. The differ-
ential activity of atezolizumab plus bevacizumab between tu-
mors with angiogenic and immunogenic phenotypes is not
robust enough for clinical decision-making.
Axitinib, a more selective and potentially less toxic vascu-
lar endothelial growth factor (VEGF) inhibitor, was com-
bined with pembrolizumab in a phase 1b study in patients
with treatment-naive advanced RCC. The combination was
tolerable and showed promising antitumor activity [23].
The combination has also shown significantly im-
proved OS and PFS versus sunitinib as first-line therapy
for advanced or metastatic RCC in the KEYNOTE-426
trial [24]. Axitinib has also been evaluated in combin-
ation with avelumab in the JAVELIN renal 100 trial,
with manageable toxicity and encouraging antitumor ac-
tivity in preliminary analysis [25]. The combination sig-
nificantly improved PFS in patients with PD-L1+
expression, with PFS and ORR benefits also observed in
patients irrespective of PD-L1 expression and across all
prognostic risk groups [26].
Tyrosine kinase inhibitor plus immunotherapy combi-
nations have shown an efficacy signal in all risk groups
but have not been compared with ipilimumab plus nivo-
lumab. Axitinib plus pembrolizumab data are awaited to
assess whether there is any advantage of anti-PD-1 ver-
sus anti-PD-L1 in RCC. Another consideration moving
forward is that heterogeneity is particularly marked in
RCC. Tumor mutational burden (TMB) is modest with
no correlation with activity of atezoluzimab plus bevaci-
zumab. RCC has the highest pan-cancer proportion and
number of indel mutations, with evidence suggesting
these are a highly immunogenic mutational class which
can trigger an increased abundance of neoantigens [27].
Identification of truncal neo-antigens may provide a tar-
get for cellular therapies.
Key points
 Combination immunotherapy with ipilimumab plus
nivolumab represents a new standard of care for
intermediate and poor risk metastatic RCC patients
 Combinations of anti-PD1 or PDL1 antibodies with
anti-VEGF agents have shown superiority to anti-
VEGF agents alone and will become an option for
all prognostic groups of patients with metastatic
RCC.
 PDL-1 expression is not an adequate biomarker in
RCC to direct therapeutic decisions.
Immunotherapy for ovarian cancer. How to move forward
Multiple clinical studies demonstrate a correlation be-
tween TILs and survival in ovarian cancer, independent
of tumor grade, stage or histologic subtype [28]. PD-1/
PD-L1 inhibitors have demonstrated encouraging but
modest activity in recurrent ovarian cancer, suggesting
an opportunity for combinations. In KEYNOTE-100,
pembrolizumab was associated with antitumor activity
in patients with recurrent advanced ovarian cancer with
1–2 or 3–5 prior lines of therapy, with ORR increasing
with PD-L1 expression [1]. The anti PD-L1 agent avelu-
mab is also being tested in two ongoing trials in ovarian
cancer. In the JAVELIN OVARIAN 200 trial, patients
with platinum-resistant/refractory disease are random-
ized to avelumab, pegylated liposomal doxorubicin or
both combined, while in the JAVELIN OVARIAN 100
trial, previously untreated patients are randomized to
carboplatin and paclitaxel with or without avelumab be-
fore a maintenance period in which patients in the ave-
lumab arm continue on therapy while patients who
received platinum-based therapy without avelumab will
be randomized to avelumab or observation.
Other strategies involve immunotherapy in combin-
ation. In the ENGOT-ov39 trial (IMagyn050), post-
surgery patients will be randomized to carboplatin plus
paclitaxel plus bevacizumab with or without atezolizumab
with initial treatment followed by maintenance bevacizu-
mab with or without atezolizumab until completion, tox-
icity or recurrence. Pre-clinical data have also suggested
synergy between anti-PD-1 therapy and poly-ADP ribose
polymerase (PARP) inhibition. PARP inhibitors up-
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regulate PD-L1 expression in preclinical models which
could potentiate an anti-tumor immune response. Nira-
parib is an oral PARP inhibitor approved for maintenance
treatment of recurrent ovarian cancer. In a phase I/II
study of patents with platinum-refractory ovarian cancer,
ORR was 25% and disease control rate was 68% among 60
evaluable patients [29]. In 12 patients with BRCA-mutated
tumors, the ORR was 45%. Similar ORRs were achieved ir-
respective of homologous recombination deficiency
(HRD) and BRCA status in the platinum-resistant/refrac-
tory subgroup. Several phase III trials involving over 4000
patients are ongoing or planned to assess the combination
of anti-PD-1/PD-L1 therapy with a PARP inhibitor.
Key points
 PD-1/PD-L1 inhibitors have demonstrated
encouraging but modest activity in recurrent ovarian
cancer, suggesting an opportunity for combinations.
 Pre-clinical data have suggested synergy between
anti-PD-1 therapy and PARP inhibition, with PARP
inhibitors up-regulating PD-L1 expression in pre-
clinical models.
 Several phase III trials are ongoing or planned to
assess the combination of anti-PD-1/PD-L1 therapy
with a PARP inhibitor.
Immunotherapy: turning up the heat on breast cancer
Of the breast cancer subtypes, triple-negative breast can-
cer (TNBC) is a particularly attractive candidate for can-
cer immunotherapy. Median OS is 9–18 months in the
metastatic setting and there are few current targeted
therapy options. TNBC also has a higher rate of muta-
tional complexity and PD-L1 expression and is more
likely to harbor TILs.
In a phase I study, women with metastatic TNBC re-
ceived atezolizumab every 3 weeks until unacceptable
toxic effects or loss of clinical benefit [30]. Prior to re-
ceiving atezolizumab, most patients were heavily pre-
treated. Single agent atezolizumab was well-tolerated
and clinically active (Table 3).
Median PFS was 1.4 months by RECIST, and 1.9
months by irRC; objective response rates by RECIST
and irRC were 10 and 13%. Clinical benefit was durable,
with a median duration of response (DOR) of 21 months
by RECIST, and 25months by irRC. Exploratory analyses
identified line of therapy for advanced disease and im-
mune biomarkers as factors that may predict clinical
benefit (Table 3).
While the median OS in all patients was 8.9 months,
in first-line patients it was 17.6 months. Patients with
PD-L1 expressing tumor-infiltrating immune cells in
≥1% of the tumor area had higher ORRs and longer OS.
Levels of tumor-infiltrating immune cells > 10% was also
independently associated with higher ORRs and longer
OS. Clinical benefit was observed in some patients with
RECIST v1.1 stable or progressive disease.
Molecular characterization of atezolizumab-treated pa-
tients showed a median TMB of 4.6 Mut/Mb [31]. TMB
was not associated with either TILs or immune bio-
markers, or with clinical activity (ORR, PFS or OS). Loss
of heterozygosity, mutations in TP53, or mutations in
BRCA1/2 were not associated with clinical response to
atezolizumab. Clinical benefit from atezolizumab was
enriched in basal-like immune-activated (BLIA) and lu-
minal androgen receptor (LAR) TNBC subtypes, both of
which indicate tumors with a more active tumor im-
mune microenvironment. Higher antigen presentation
and Teff gene expression signatures were also associated
with increased clinical activity.
Standard cancer therapies can augment the activity of
immunotherapies and the combination of PD-1/PD-L1
blockade with standard chemotherapy is being evaluated
in TNBC. In the IMpassion 130 study, patients with un-
treated metastatic TNBC were randomized to atezolizu-
mab plus nab-paclitaxel or placebo plus nab-paclitaxel
until disease progression or unacceptable toxicity [32].
The combination was generally safe and well-tolerated;
adverse events that led to the discontinuation of any
agent occurred in 15.9% of the patients who received
atezolizumab plus nab-paclitaxel and in 8.2% of those
who received nab-paclitaxel monotherapy. Median PFS
was 7.2 months with atezolizumab plus nab-paclitaxel
compared with 5.5 months with nab-paclitaxel alone,
while median OS was 21.3 versus 17.6 months. In pa-
tients with PD-L1+ tumors, median PFS was 7.5 and 5.0
months and median OS was 25.0 and 15.5 months, re-
spectively. Based on these data, atezolizumab and nab-
paclitaxel received accelerated approval by the FDA. The
future is in combination immunotherapies that both
promote the induction of active T cells and relieve im-
mune suppression. These strategies should have syner-
gistic clinical activity, though could also result in
increased toxicity.
Key points
 Triple negative breast cancers (TNBC) are more
likely to harbor TILs and express PD-L1 than other
breast cancers.
 Atezolizumab monotherapy is well tolerated and has
durable clinical activity in some patients with
metastatic TNBC, with response rates of 10–13%
overall.
 The clinical activity of single agent atezolizumab is
higher when used in the first-line setting for
advanced disease, and in patients who are > PD-L1
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IC positive, with response rates of 24% and 12–16%
respectively.
 A randomized Phase 3 clinical trial of atezolizumab
with nab-paclitaxel versus placebo with nab-paclitaxel
in TNBC patients with untreated metastatic disease
demonstrated that adding atezolizumab to nab-
paclitaxel is safe and feasible, with response rates of
56% in all patients and 59% in > PD-L1 IC+ patients.
 In untreated PD-L1 IC+ TNBC patients, the
atezolizumab/nab-paclitaxel combination resulted in
a PFS benefit of 2.5 months, and an OS benefit of
9.5 months.
Immunotherapy in pancreatic cancer: lights and shadows
Studies of single-agent immunotherapy in pancreatic
ductal adenocarcinoma (PDAC) have been disappointing
with PD-1/PD-L1 checkpoint inhibitors largely ineffect-
ive. Activity of pembrolizumab has been shown only in
mismatch repair (MMR) deficient tumors, which repre-
sent only around 1% of PDAC cases [33]. PDAC is con-
sidered as a non-immunogenic, or cold, tumor type with
many mutations but very few neoantigens. PDAC offers
a strongly immune resistant and suppressive environ-
ment. Lack of response may in part be due to PDAC’s
unique TME, consisting of a dense fibrotic stroma and a
scarcity of TILs. However, it is not the physical barrier
of the stroma but rather an oncogene-driven immuno-
suppressive network that excludes effector T cells. In
reality, nearly all PDAC samples harbor potentially
targetable neoantigens. In fact, T cells are present but
generally show a reduced activation signature and
markers of antigen presentation are associated with a re-
duced signature of markers characterizing cytotoxic T
cells [34]. These findings suggest that despite the pres-
ence of tumor specific neoepitopes, T cell activation is
actively suppressed in PDAC. Interestingly, contrary to
other tumors, mutation load in PDAC is inversely related
with T-cell activity.
Chemokines and their receptors play a critical role in
conditioning metastatic niche, immunosuppressive sta-
tus and the TME. They help to recruit to tumor side
and to ‘corrupt’ neutrophils, monocytes/macrophages
and fibroblasts with different properties which, together,
help tumor growth and metastatic spread. CXCR2 sig-
naling is upregulated in myeloid-derived suppressor cells
and in pancreatic cancer and CXCR2 inhibition in mice
enhances T cell entry and confers sensitivity to anti-PD-
1 therapy [35]. Another possible approach is targeting
macrophages through CSF1R inhibitors. Macrophages
functionally contribute to the squamous subtype of hu-
man PDAC and inhibition of CSF1R alters the TME and
results in an enhanced T cell immune response [36].
Long-term survivors of PDAC display evidence of en-
hanced tumor-specific T-cell responses that are associ-
ated with unique neoepitope quality but not quantity
[37]. Multiplexed immunohistochemistry revealed no
difference in the absolute number of CD3+ T cells be-
tween long-term and short-term survivors. However,
Table 3. Clinical Activity Associated with Atezolizumab Monotherapy in the Phase 1 PCD48989g Study
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there was a threefold increase in cytotoxic CD8+ T cells,
in long-term survivors and an increase in the number of
cytolytic CD8+ T cells, including CD3+, CD8+, and
granzyme B+ cells. Using whole-exome sequencing and
in silico neoantigen prediction, tumors with both the
highest neoantigen number and the most abundant
CD8+ T-cell infiltrates, but neither alone, stratified pa-
tients with the longest survival. Long-term survivors dis-
played persistent T cell clones that cross-react with
tumor neoepitopes and homologous microbial antigens;
the theory of molecular mimicry postulates that T cell
receptors that can recognize pathogenic antigens can
also recognize non-pathogenic antigens. This could
guide the selection of patients for immuno-oncology
treatment protocols and for the design of individualized
peptide-based vaccines, selecting peptides that are pre-
dicted by this computation of neoepitope quality to be
the most likely to generate an effective immune
response.
Priming or boosting of T cell responses is required for
therapeutic effect and sensitization to checkpoint block-
ade in PDAC. Most tumors are unresponsive to immune
checkpoint blockade, especially if deep immunosuppres-
sion in the tumor develops prior to and prevents T cell
immunosurveillance. Failed or frustrated T cell priming
often needs repair before successful sensitization to PD-
1/PD-L1 blockade. Large numbers of clinical trials of
checkpoint inhibitors combined with other agents are
planned or ongoing in an effort to achieve this goal.
Key points
 PDAC offers a strongly immune resistant and
suppressive environment. and studies of single-agent
immunotherapy in PDAC have been disappointing
with PD-1/PD-L1 checkpoint inhibitors largely
ineffective.
 Despite the presence of tumor specific neoepitopes,
T cell activation is actively suppressed in PDAC, and
contrary to other tumors, mutation load in PDAC is
inversely related with T-cell activity.
 Priming or boosting of T cell responses is required
for therapeutic effect and sensitization to checkpoint
blockade in PDAC and large numbers of clinical
trials of checkpoint inhibitors combined with other
agents are planned or ongoing in an effort to achieve
this goal.
Immunotherapy for brain cancer
In patients with melanoma brain metastases, nivolumab
plus ipilimumab resulted in an intracranial clinical benefit
of 57% (26% complete responses) with intracranial activity
concordant with extracranial activity [38]. However, in pa-
tients with recurrent glioblastoma, treatment with
nivolumab with or without ipilimumab resulted in only
three of 40 patients achieving a partial response and eight
having stable disease for ≥12weeks [39] (Table 4).
Nivolumab monotherapy was better tolerated than
nivolumab plus ipilimumab but the monotherapy arm
was closed early due to poor OS. Compared with melan-
oma brain metastases, glioblastoma is more infiltrative,
and thus more protected by the blood-brain barrier with
penetration of IgG antibodies of only around 4%. Recur-
rent glioblastoma may have more profound lymphope-
nia. Moreover, melanomas have more mutations,
thereby more neoantigens. Gliobastoma is considered a
cold tumor medium with a low TMB, although chemo-
therapy with temozolomide often induces hypermuta-
tion. However, whether cold tumor status is solely
attributable to the low mutation load is unclear. Case re-
ports on durable responses to immune checkpoint inhib-
ition in hypermutant glioblastoma arising from primary
genetic predisposition or secondary MMR deficiency
suggest yes, whereas other data indicate tumor muta-
tional load was not associated with CD8+ T cell infiltra-
tion or PD-1/PD-L1 expression based on evaluation of
198 glioblastoma cases [40].
There is evidence to suggest the brain is surprisingly sus-
ceptible to adoptively transferred T-cells. T cell receptor-
targeting MAGE-A3 has been reported to cause severe
damage to brain grey matter, resulting in two deaths. High
IL-6, IL-2, granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) and VEGF levels in cerebrospinal fluid (CSF)
have been observed during neurotoxicity, with both CD20
CAR and non-CAR T cells accumulating in the CSF and in
the brain parenchyma. There is also evidence of endothelial
activation, disseminated intravascular coagulation, capillary
leak, and increased blood-brain barrier permeability in the
CD19-CAR setting. A single dose of peripherally infused
EGFRvIII-directed CAR T cells mediated antigen loss and
induced adaptive resistance in patients with recurrent glio-
blastoma [41]. In situ evaluation of the tumor environment
demonstrated increased and robust expression of inhibitory
molecules and infiltration by regulatory T cells after
CART-EGFRvIII infusion. Overcoming adaptive changes in
the local TME and addressing antigen heterogeneity may
improve the efficacy of EGFRvIII-directed strategies in
glioblastoma.
Key points
 Anti-PD-1 agents have shown efficacy in patients
with melanoma brain metastases but less so in
patients with recurrent glioblastoma, which is more
protected by the blood-brain barrier and has with a
lower TMB.
 There is evidence to suggest the brain is surprisingly
susceptible to adoptively transferred T-cells. T cell
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receptor-targeting MAGE-A3 has been reported to
cause severe damage to brain grey matter.
 Overcoming adaptive changes in the local TME and
addressing antigen heterogeneity may improve the
efficacy of EGFRvIII-directed strategies in
glioblastoma.
Immunotherapy evolution for lung carcinoma
Single-agent pembrolizumab is now the standard of care
for advanced NSCLC with PD-L1 expression of ≥50%
[42], although it is not superior to chemotherapy in
NSCLC PD-L1 < 50%. Nivolumab is not superior to
chemotherapy regardless of PD-L1 expression [43]. Re-
sults from two phase III randomized trials of atezolizumab
versus chemotherapy are pending.
With regard to anti-PD-1/PD-L1 therapy in combin-
ation with chemotherapy, pembrolizumab plus peme-
trexed and a platinum-based drug significantly prolonged
OS versus chemotherapy alone in patients with metastatic
non-squamous NSCLC [44]. Improved OS was seen
across PD-L1 subgroups. The addition of pembrolizumab
to chemotherapy of carboplatin plus paclitaxel or nab-
paclitaxel also resulted in significantly longer OS and PFS
than chemotherapy alone in patients with previously un-
treated metastatic, squamous NSCLC [45]. First-line treat-
ment with nivolumab plus chemotherapy also improved
PFS versus chemotherapy alone in patients with non-
squamous NSCLC with PD-L1 expression < 1% [46].
Phase III randomized trials have failed to show OS
superiority for atezolizumab plus chemotherapy compared
with chemotherapy alone except for the combination of
atezolizumab with carboplatin, paclitaxel and bevacizu-
mab in non-squamous patients in the Impower 150 trial
[47]. Atezolizumab plus chemotherapy improved PFS but
failed to show a survival benefit as first-line treatment in
stage IV squamous NSCLC [48].
Combined immunotherapy may also have a role in the
treatment of NSCLC. However, the combination of tre-
melimumab plus durvalumab did not improve OS or
PFS compared with chemotherapy in unselected patients
with lung cancer [49]. In another phase III trial, PFS in
NSCLC patients with a high TMB was significantly lon-
ger with nivolumab plus ipilimumab than with chemo-
therapy [50]. The benefit of nivolumab plus ipilimumab
over chemotherapy was broadly consistent within sub-
groups, including patients with a PD-L1 expression level
of ≥ or < 1%, although results seemed to be more im-
pressive in PD-L1 < 1% patients. Recent doubts about
the predictive role of TMB, with a survival gain even in
low TMB patients, means nivolumab plus ipilimumab
could offer a chemotherapy-free option for advanced
NSCLC regardless of PD-L1 and TMB status.
Key points
 Single-agent pembrolizumab is now the standard of
care for advanced NSCLC with PD-L1 expression of
≥50%.
Table 4. Comparison of nivolumab plus ipilimumab in glioblastoma and melanoma brain metastases
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 Combined immunotherapy may also have a role in
the treatment of NSCLC with PFS in NSCLC
patients with a high TMB significantly longer with
nivolumab plus ipilimumab than with
chemotherapy.
 Recent doubts about the predictive role of TMB,
with a survival gain even in low TMB patients,
means nivolumab plus ipilimumab could offer a
chemotherapy-free option for advanced NSCLC
regardless of PD-L1 and TMB status.
Immunotherapy for Merkel cell carcinoma: present and
future
Merkel cell carcinoma (MCC) is a rare, aggressive skin
cancer associated with poor survival. In a phase I trial,
first-line therapy with pembrolizumab in patients with
advanced MCC was associated with an ORR of 56%,
with responses in patients with and without virus-
positive tumors [51]. Subsequent data with a median
follow-up of 8.6 months showed durable tumor control,
a favorable OS rate of 68% at 18 months and a manage-
able safety profile [52]. Similar results have been ob-
served with nivolumab, which induced rapid and durable
tumor regressions in treatment-naive and previously-
treated patients with advanced MCC (ORR 68%) in both
virus-positive and virus-negative tumors [53].
In a phase II trial in patients with stage IV chemotherapy-
refractory MCC, avelumab was associated with durable re-
sponses and an ORR of 31.8% [54]. Avelumab was also well
tolerated with five grade 3 treatment-related adverse events
occurring in four (5%) patients. In subsequent follow-up, 1-
year PFS rate was 30% and 1-year OS rate was 52% [55].
Median OS was 12.9months. Subgroup analyses suggested
a higher probability of response in patients receiving fewer
prior lines of systemic therapy, with a lower baseline disease
burden, and with PD-L1+ tumors; however, durable re-
sponses occurred irrespective of baseline factors, including
tumor Merkel cell polyomavirus status.
Avelumab has also achieved high rates of response and
was well tolerated as first-line therapy in patients with
distant metastatic MCC, with a confirmed ORR of 62.1%
[56]. These data are supported by results of a European
expanded access programme, which has reported
physician-assessed objective responses in 54.3% (n = 57)
of patients and a disease control rate (DCR) of 75% [57].
Taken together, these data suggest that checkpoint in-
hibitors may represent a new standard of care for ad-
vanced MCC.
PD-1/PD-L1 checkpoint inhibitors may also have a
role as neo-adjuvant or adjuvant therapy. In the first trial
of anti-PD-1 treatment in the neoadjuvant setting for re-
sectable MCC, nivolumab administered for 4 weeks be-
fore surgery was safe and induced substantial radiologic
and pathologic tumor regressions in 45 and 65% of
patients, respectively [58]. Among 21 patients followed
after surgery, all were progression-free at 6 months and
two had relapsed at 12 months. Nivolumab and avelu-
mab are also being assessed in adjuvant trials.
Key points
 Durable tumor control and a manageable safety
profile have been shown with pembrolizumab and
nivolumab in patients with Merkel cell carcinoma.
 Avelumab was also associated with durable
responses and was well tolerated in patients with
stage IV chemotherapy-refractory MCC and in
patients with distant metastatic MCC.
 Taken together, these data suggest that checkpoint
inhibitors may represent a new standard of care for
advanced MCC.
 PD-1/PD-L1 checkpoint inhibitors may also have a
role as neo-adjuvant or adjuvant therapy.
Drivers of immune responses
Metabolic properties of immune cells in renal cell
carcinoma: opportunities for therapeutic optimization
Clear cell RCC has the highest CD8a signature of all
non-lymphoid solid tumor types and RCC is often, but
not always, immune responsive. PD-1 checkpoint inhib-
ition can be effective, but only in around 25% of patients
with clear cell RCC and duration of responses can be
limited.
Clear cell RCC CD8 TILs have been shown to be pheno-
typically distinct and poorly functional [59]. CD8 TILs
from clear cell RCC patients appear effector-memory-like
and are PD-1high, which may indicate chronic stimulation
and a suppressed or exhausted state. Clear cell RCC CD8
TILs also had a broad set of defects in glucose uptake, gly-
colysis, and mitochondrial dynamics and function, which
contribute to their limited capacity to activate. RCC TILs
fail to utilize glucose for stimulation, in spite of access to
adequate glucose and appropriate expression of nutrient
tools. T cell activation can be partially restored with pyru-
vate or mitochondrial reactive oxygen species (ROS) scav-
engers. Metabolic adaptations of TILs to the clear cell
RCC TME may form a barrier to antitumor immunity and
immune-checkpoint therapy.
Mitochondrial deficiencies appear to play key roles in
the inability of TILs to eliminate cancer cells. Mitochon-
dria in clear cell RCC CD8 TILs are abundant but ap-
pear small and highly fragmented compared with
normal healthy CD8 T cell mitochondria, and are highly
polarized with increased mitochondrial ROS. Tumor-
specific CD8 T cells with mitochondrial hyperpolariza-
tion express inhibitory receptors and have limited ability
to control tumors in studies of adoptive T cell therapy.
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Metabolic defects contribute to poor T cell function in
tumors. Immune therapies can, however, reactivate T
cells to promote antitumor immunity, if only in a rela-
tively small subset. It is important to understand mecha-
nisms that may restrict T cell metabolism in clear cell
RCC in order to provide new markers for T cell function
and potential targets to improve T cell-mediated antitu-
mor immunity.
Key points
 PD-1 checkpoint inhibition can be effective in
patients with clear cell RCC, but only in around 25%
and duration of responses can be limited.
 Metabolic adaptations of TILs to the clear cell RCC
TME may form a barrier to antitumor immunity
and immune-checkpoint therapy.
 Mitochondria in clear cell RCC CD8 TILs are
abundant but appear small and highly fragmented
compared with normal healthy CD8 T cell
mitochondria and are highly polarized with
increased mitochondrial ROS.
 It is important to understand mechanisms that may
restrict T cell metabolism in clear cell RCC in order
to provide new markers for T cell function and
potential targets to improve T cell-mediated
antitumor immunity.
Cancer vaccines and strategy to develop combination
immunotherapy with T cell agonists
Advanced cancers tend to be heterogeneous so complete
response will require immunity against a large number
of antigens. As such, a goal of treatment should be to
provide a large number of relevant antigens in order to
activate a broad spectrum of tumor-reactive T cells. One
explanation for how T-cells become activated against
tumor antigens is by cross-presentation, during which
tumor proteins are phagocytosed, digested with protea-
somes, and presented via major histocompatibility com-
plex class I to T cells for activation. Two hypothesized
classes of tumor-associated proteins, defective ribosomal
products (DRiPs) and short-lived proteins (SLiPs), are
abundant in tumor cells, but are unstable and only tran-
siently expressed before being degraded by tumor cell
proteosomes. It has been hypothesized that these DRiP/
SLiP antigens could potentially facilitate anti-tumor im-
mune responses and could form the basis of a novel
anti-tumor vaccine.
The DRibbles multi-valent vaccine is created by dis-
rupting degradation of intracellular proteins by the ubi-
quitin proteasome system. It consists of autophagosome
vesicles that are enriched with DRiPs and SLiPs, known
tumor-associated antigens, mediators of innate immun-
ity, and surface markers that encourage phagocytosis
and cross-presentation by antigen-presenting cells. The
first ‘off-the-shelf’ allogeneic human DRibbles vaccine,
DPV-001, was derived from autophagosome products of
two NSCLC cell lines, one of mixed histology and one
from an adenocarcinoma [60]. It contains multiple TLR
agonists and > 130 potential NSCLC antigens, many as
prospective altered-peptide ligands. DPV-001 cancer
vaccine induces and/or augments immunity against
many relevant cancer antigens. In a phase II trial, pa-
tients with stage III NSCLC received cyclophosphamide
induction therapy, before being randomized to DPV-001
alone, with GM-CSF or with imiquimod [61]. Patients
receiving DPV-001 had a significant increase in total
(CD4 and CD8) T cells over that seen with controls and
the increase in CD4 T cells was similar to that seen in
patients receiving ipilimumab. Vaccination induced or
increased IgG antibody responses against targets over-
expressed by NSCLC, correlating with activated Th1
cells in whole blood samples. New or augmented anti-
body responses were observed with continued vaccin-
ation [62].
Antibody responses to antigens over-expressed in
NSCLC were detected as ‘waves’ with possible co-
coordination of antibody and T cell responses after vac-
cination. T cell contraction, a natural component of a T
cell response to antigen, may be responsible for these
variations and raises the possibility of combining vaccin-
ation with T cell agonists that blunt contraction by aug-
menting T cell expansion and sustaining antigen-specific
T cells. For example, OX40 ligation increases IL-2 pro-
duction and IL-2R expression and enhances CD4 and
CD8 T cell effector differentiation and the generation of
long-lived memory cells [63]. A clinical trial is planned
in patients with advanced TNBC to assess a combination
strategy involving DPV-001 vaccine plus a T cell agonist
with or without checkpoint blockade.
The development of personalized vaccine therapy that
integrates patient-specific neoantigens into the ‘off-the-
shelf’ DPV-001 vaccine is also planned. In this approach,
patients can begin vaccinations with DPV-001, prior to
obtaining the tumor biopsy used for neoantigen deter-
mination and personalized vaccine production.
Key points
 A goal of treatment is to provide a large number of
relevant antigens in order to activate a broad
spectrum of tumor-reactive T cells.
 DRiP/SLiP antigens could potentially facilitate anti-
tumor immune responses and could form the basis
of a novel anti-tumor vaccine.
 DPV-001, derived from autophagosome products of
two NSCLC cell lines, contains multiple TLR
agonists and > 130 potential NSCLC antigens, many
Ascierto et al. Journal for ImmunoTherapy of Cancer           (2019) 7:332 Page 13 of 20
as prospective altered-peptide ligands and induces
and/or augments immunity against many relevant
cancer antigens.
 The development of personalized vaccine therapy
that integrates patient-specific neoantigens into the
‘off-the-shelf’ DPV-001 vaccine is planned.
Next target for immune checkpoint blockade in
melanoma
Chronic antigen exposure can lead to T cell exhaustion.
Exhausted T cells upregulate multiple inhibitory recep-
tors/immune checkpoints, including PD-1, CTLA-4, TIM-
3, LAG-3, and T Cell ITIM Domain (TIGIT) (Fig. 2).
These bind to their ligands that are highly expressed in the
TME. There is also evidence of additive/synergistic effects on
tumor antigen-specific CD8+ T cell expansion and function
with dual blockade with anti-PD-1/PD-L1 antibodies together
with antibodies targeting additional inhibitory receptors.
TIM-3 is a negative regulator of Th1 immune re-
sponses and spontaneous NY-ESO-1-specific CD8+ T
cells as well as CD8+ TILs in solid tumors upregulate
PD-1 and TIM-3. Ex vivo TIM-3 + PD1+ NY-ESO-1-
specific CD8+ T cells and TILs represent a dysfunctional
T cell population. TIM-3 blockade enhanced cytokine
production and proliferation of NY-ESO-1-specific
CD8+ T cells upon prolonged antigen stimulation is
additive/synergistic with PD-1 blockade [64]. TSR-022 is
a humanized anti-TIM-3 IgG4 antibody that binds to
TIM-3 with high affinity and has potent in vitro and
in vivo activity. In part 1 of the AMBER study, TSR-022
was dose-escalated to a 1200mg flat dose with no dose-
limiting toxicities. In part 2, TSR-022 was combined
with TSR-024, an anti-PD-1 agent, in patients PD-1 re-
fractory melanoma and NSCLC [65]. TSR-022 in com-
bination with TSR-042 demonstrated clinical activity
with objective responses in patients with post-PD-1
NSCLC and melanoma. The combination was also well
tolerated with incidence of grade ≥ 3 treatment-related
adverse events of 6.7%, with increased lipase and
maculo-papular rash the most frequent.
The inhibitory receptor TIGIT and its competing cost-
imulatory receptor DNAM-1/CD226 regulate innate and
Fig. 2 Immunoregulatory pathways in the tumor microenvironment and T cell dysfunction
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adaptive immune responses to tumors. TIGIT and PD-1
regulate the expansion and function of tumor antigen-
specific CD8+ T cells and CD8+ TILs in melanoma
patients [66]. TIGIT ligands are highly expressed in
metastatic melanoma and many other solid tumors and
dual TIGIT/PD-1 blockade increases the proliferation of
tumor antigen-specific CD8+ T cells. TIGIT is also
highly upregulated by human Tregs in the TME,
whereas there is decreased expression of its competing
co-stimulatory receptor CD226 [67]. In contrast to
TIGIT, CD226 disrupts Treg-mediated suppression and
stability in the periphery and at tumor sites. PVR-
mediated activation of CD226 partially reverses TIGIT+
CD4+ Treg-induced immunosuppression and decreases
Foxp3 expression in TIGIT+ CD4+ Tregs of patients
with advanced melanoma. A high TIGIT/CD226 ratio in
Tregs together with high PVR expression in the TME
promotes Treg stability and suppressive functions.
Altogether, our findings support the development of
combinatorial therapies to target the TIGIT/CD226 axis
in solid tumors to augment innate and adaptive immune
responses to cancer.
Key points
 TSR-022 is a humanized anti-TIM-3 IgG4 antibody
that binds to TIM-3 with high affinity and has
potent in vitro and in vivo activity.
 TSR-022 in combination with TSR-042
demonstrated clinical activity with objective
responses in patients with post-PD-1 NSCLC and
melanoma.
 The inhibitory receptor TIGIT and its competing
costimulatory receptor DNAM-1/CD226 regulate
innate and adaptive immune responses to tumors.
 Data support the development of combinatorial
therapies to target the TIGIT/CD226 axis in solid
tumors to augment innate and adaptive immune
responses to cancer.
Targeting immune escape of head and neck cancer:
dangers and opportunities
The incidence of HPV+ head and neck tumors is in-
creasing and these are typically more responsive to treat-
ment than tobacco and alcohol-related cancers, which
may in part be immune-mediated. PD-1+ CD8+ T cells
with an activated phenotype may be a favourable prog-
nostic biomarker in HPV+ patients. PD-1 expression has
been shown to be upregulated on head and neck cancer
(HNC) patient TILs, with a higher frequency of PD-1+
TILs in HPV+ patients [68]. Higher fractions of PD-1low
T cells were associated with HPV positivity and better
outcome. As such, the extent of PD-1 expression on
CD8+ TILs may be a potential biomarker for anti-PD-1-
based immunotherapy. Total and PD-1+ NK cells are
also significantly higher in the circulation of HNC pa-
tients and are associated with improved clinical out-
come. These cells are also enriched in the TME.
Elevated expression of NKp46 in HNC specimens
(TCGA) associates with better survival and strongly cor-
relates with PD-1 but not TIM-3 or CTLA-4 [69]. PD-1
blockade increases cetuximab-mediated NK cell activa-
tion against HNC targets with high PD-L1 expression.
Therefore, blocking the PD-1/PD-L1 axis may be a use-
ful strategy to reverse immune evasion of HNC tumors
with high PD-L1 expression during cetuximab therapy
by reversing NK cell dysfunction.
In the Active8 randomized clinical trial, the addition
of the TLR-8 agonist motolimod to the EXTREME regi-
men was well tolerated but did not improve PFS or OS
in the overall population [70]. However, significant bene-
fits were observed in HPV+ patients, with significantly
longer PFS and OS, as well as in patients with injection
site reactions, suggesting that TLR-8 stimulation may
benefit subset- and biomarker-selected patients.
The addition of nivolumab to a cetuximab-radiotherapy
regimen for patients with newly diagnosed intermediate and
high-risk local-regionally advanced SCCHN has been shown
to be safe and feasible in the ongoing RTOG3504 trial [71].
The JAVELIN Head and Neck 100 study is a phase III ran-
domized clinical trial assessing the efficacy of avelumab in
combination with chemoradiotherapy compared with pla-
cebo in combination with chemoradiation for high-risk
SCCHN, while UPCI 15–132 is assessing sequential versus
concomitant pembrolizumab plus chemoradiation.
Immunotherapy is also being assessed in the neoadju-
vant setting, with the CheckMate 358 trial investigating
the safety and feasibility of neoadjuvant nivolumab in
patients with resectable HPV+/− SCCHN. In 29 patients,
nivolumab was well tolerated, with no delays to surgery
due to adverse events, and resulted in tumor reductions
within 1 month in nearly half of evaluable patients [72].
Key points
 PD-1+ expression may be a favourable prognostic
biomarker in HPV+ HNC patients.
 Blocking the PD-1/PD-L1 axis may be a useful strat-
egy to reverse immune evasion of HNC tumors with
high PD-L1 expression during cetuximab therapy by
reversing NK cell dysfunction.
 The addition of nivolumab to a cetuximab-
radiotherapy regimen for patients with newly diagnosed
intermediate and high-risk local-regionally advanced
SCCHN has been shown to be safe and feasible.
 The safety and feasibility of neoadjuvant nivolumab
is also being evaluated in patients with resectable
HPV+/− SCCHN.
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Systems immunology and tumor microenvironment
Immunophenotyping of tumors may provide prognostic in-
formation and the Immunoscore was first proposed as a po-
tential approach for the classification of cancer in 2012.
More recently, international validation has shown that it
provides a reliable estimate of the risk of recurrence in pa-
tients with colon cancer and it has been proposed as a new
component of a TNM-Immune classification of cancer [73].
The efficacy of immunotherapies depends on the immune
contexture and the ability to unleash pre-existing immunity.
Tumors can be categized on the basis of their immune sta-
tus as immune-infiltrated (hot), altered (Immune-excluded
or immune-suppressed) and immune desert (cold) and it is
critical to understand the mechanisms responsible for each
in order to boost antitumor immunity [74]..
A key question is whether there is an immune escape at
the metastatic stage? In analysis of resected metastases
from colorectal cancer patients, Immunoscore and T and
B cell score in the least immune-infiltrated metastases
were the strongest predictors for disease-free survival and
OS [75]. Assessment of immune cell types of 603 whole-
slide metastases and primary colorectal tumors from 222
colorectal cancer patients showed high intra-metastasis,
inter-metastasis and intra-patient heterogeneity [76].
Small metastases frequently had a low Immunoscore and
T and B cell score, while a high Immunoscore was associ-
ated with a lower number of metastases. The Immuno-
score from a single biopsy was more reliable than PD-L1
expression as a predictor of survival.
Current theories of cancer evolution are tumor cell-centric
with none involving a role of the immune system. A parallel
selection model of metastatic progression, where branched
evolution in space and time could be traced back to immune-
escaping clones has now been proposed [77]. Multiplexed
analyses reveal highly heterogeneous genomic patterns and
immune cell infiltration between metastases and that clonal
evolution patterns during metastatic progression depend on
the immune contexture at the metastatic site. Transmission
of tumor clones occurs from one metastasis to consecutive
metastases with multiparallel tumor evolution and diverse
tumor clones. Non-recurrent eliminated clones are immunoe-
dited while persistent clones are immune-privileged (not
immunoedited), despite the presence of TILs. Non-recurrent
clones (< 4 years) have a low immunoediting score. For
immunoediting to occur, a high Immunoscore is necessary
but alone is not sufficient, since high-Immunoscore may not
show immunoediting. Characterization of immune-privileged
metastases revealed tumor-intrinsic and tumor-extrinsic
mechanisms of escape, with different escape mechanisms de-
lineated by lack of adaptive immunity or immunoediting.
Immunoediting and Immunoscore are predictive factors of
metastasis recurrence. Distance between CD3+ cells and
Ki67+ tumor cells as well as metastasis size are also associated
with metastatic dissemination. The lowest recurrence risk
was associated with high Immunoscore, occurrence of immu-
noediting, and low tumor burden. This work represents the
first demonstration in Human that tumor clone dissemin-
ation are dependent upon the immune system, and more pre-
cisely upon the immune contexture, the Immunoscore and
the immunoediting [77].
Because of different escape mechanisms, there is a
need for different combination therapies.
Key points
The Immunoscore has been proposed as a new compo-
nent of a TNM-Immune classification of cancer.
 Tumors can be categized on the basis of their
immune status as immune-infiltrated (hot), altered
(immune-excluded or immune-suppressed) and
immune desert (cold) and it is critical to understand
the mechanisms responsible for each in order to
boost antitumor immunity.
 Analysis of resected metastases from colorectal
cancer patients showed that Immunoscore and T
and B cell score in the least immune-infiltrated
metastases were the strongest predictors for disease-
free survival and OS.
 The Immunoscore from a single biopsy may be a
more reliable than PD-L1 expression as a predictor
of survival.
 Immunoediting and Immunoscore are predictive
factors of metastasis recurrence.
Conclusions
Immunotherapy of cancer has made major advances in re-
cent years and checkpoint inhibitors have become recog-
nised as a standard of care in several different types of
cancer. Increased understanding of the complex interac-
tions between tumours and the host immune response
(including the mechanistic impact of combination therap-
ies and tumor and immune cell metabolism) and the
therapeutic implications of these findings is leading to the
development of novel therapeutic strategies across differ-
ent cancers. In particular, research into a wide range of
different and potentially synergistic immunotherapy com-
binations is ongoing, novel cellular therapies are being
fine-tuned, and the role for vaccines is being better eluci-
dated and will soon lead to more durable responses for
higher numbers of patients.
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